Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $22
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $22
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $21 to $22
Buy Rating Affirmed for Perspective Therapeutics Amid Promising Early-Stage Drug Results for Melanoma Treatment
Perspective Therapeutics Analyst Ratings
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Raises Target Price to $22
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $25
LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $24
Buy Rating on Perspective Therapeutics Backed by Promising VMT-alpha-NET Clinical Results
Wedbush Initiates Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $25
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $24
Perspective Therapeutics Price Target Announced at $21.00/Share by Truist Securities
Perspective Therapeutics Analyst Ratings
Truist Financial Initiates Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $21
Perspective Therapeutics Price Target Cut to $27.00/Share From $29.00 by RBC Capital
Perspective Therapeutics Analyst Ratings
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $27